BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase III
Regeneron (REGN) Release: EYLEA® (aflibercept) Injection Recommended For Approval For The Treatment Of Visual Impairment Due To Macular Edema Secondary To Central Or Branch Retinal Vein Occlusion In The European Union 1/23/2015
ALPHAEON Begins Phase 3 Study For Its Neurotoxin, EVOSYAL 1/22/2015
Shire plc Release: Positive Response From European Decentralised Procedure For Elvanse Adult® (lisdexamfetamine dimesylate) In Adults With ADHD 1/22/2015
FDA Removes Partial Clinical Hold on CytRx Corporation (CYTR)'s Brain Cancer Trials 1/21/2015
Celator Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CPX-351 For The Treatment Of Elderly Patients With Secondary Acute Myeloid Leukemia 1/20/2015
Merrimack Pharmaceuticals Inc. (MACK) Presents Additional Analyses Of Phase 3 MM-398 NAPOLI-1 Study At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 1/20/2015
Actavis (ACT), Gedeon Richter Ltd. (RIG2.F) Say Key Drug Cariprazine Effective on Schizophrenia Relapse 1/20/2015
Choroideremia Research Foundation Release: Groundbreaking Gene Therapy Trial Begins In Philadelphia 1/20/2015
TauRx Therapeutics Release: First Evidence Of Potential Efficacy Of Tau Aggregation Inhibitor Therapy In Alzheimer's Disease 1/20/2015
Clinical Study Results Presented At The 2015 Gastrointestinal Cancer Symposium Support Utility Of Trovagene's Precision Cancer Monitoring Platform In Colorectal And Pancreatic Cancer Patients 1/20/2015
The New Billion Dollar Tekmira (TKMR) Includes Promising Hep B Drug 1/20/2015
PharmaEngine, Inc. Announces Expanded Analyses Of Phase 3 MM-398 NAPOLI-1 Study Presented At The 2015 American Society of Clinical Oncology GI Substantiate The Positive Results Of MM-398 In Combination With 5-FU/LV 1/19/2015
Marathon Pharmaceuticals, LLC Receives FDA Fast Track Designation For Deflazacort As A Potential Treatment For Duchenne Muscular Dystrophy 1/19/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer 1/16/2015
J.P. Morgan: AstraZeneca PLC (AZN) CEO Says He's Not Worried About Pricing Pressure 1/15/2015
Janssen Pharmaceutical Inc. Release: Real-World Data Published In Clinical Cardiology Show Consistent Safety Performance Of Once-Daily XARELTO® 1/14/2015
Antares Pharma, Inc. (ATRS) Announces Update To QuickShot® Testosterone Program 1/13/2015
INSYS Therapeutics To Initiate Five Phase 3 Clinical Trials In 2015 1/13/2015
AB Science (AB.PA): The Data and Safety Monitoring Board Recommends The Continuation Of Phase 3 Study Of Masitinib In Amyotrophic Lateral Sclerosis 1/13/2015
Breaking: J.P. Morgan: BioMarin (BMRN) Takes Shot at Sarepta (SRPT), Says DMD Drug Has Better Results So Far 1/13/2015
J.P. Morgan: Celgene (CELG) to Fast-Track Crohn's Drug, Provides Estimates Up to 2020 1/13/2015
Bristol-Myers Squibb Company (BMY) Study Halted After Opdivo Meets Efficacy Endpoint 1/13/2015
Frost & Sullivan Releases Drug Launch And Phase 3 Trial Watch List For Top Therapeutic Areas 1/13/2015
Pharmamar Will Start A Phase 3 Study Of PM1183 In Combination With Doxorubicin In Relapsed SCLC 1/13/2015
Regeneron (REGN), Sanofi (SAN.PA) Show Off Positive Cholesterol Drug Data 1/12/2015
Aerie Pharmaceuticals, Inc. (AERI) Announces Acceleration Of Expected Timeline For Reporting Efficacy Results From Phase 3 Registration Trial (“Rocket 1”) Of Rhopressa™ 1/12/2015
The Lancet Oncology Publishes Phase III Data Showing Giotrif® (Afatinib*) Significantly Extended Overall Survival Of Lung Cancer Patients With The Most Common EGFR Mutation Over Chemotherapy 1/12/2015
Bristol-Myers Squibb Company (BMY) Release: CheckMate -017, A Phase 3 Study Of Opdivo (Nivolumab) Compared To Docetaxel In Patients With Second-Line Squamous Cell Non-Small Cell Lung Cancer, Stopped Early 1/12/2015
Radius (RDUS) Announces Follow-Up On The Positive Phase 3 Top-Line Results For Its Investigational Drug Abaloparatide-SC In Postmenopausal Women With Severe Osteoporosis 1/12/2015
Portola Pharmaceuticals, Inc. Initiates Phase 4 Study To Support Accelerated Approval Of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote 1/12/2015
Tesaro, Inc. (TSRO) Announces Expansion Of Niraparib Clinical Program And Outlines Late-Stage Program Milestones For 2015 1/12/2015
The Lancet Oncology Publishes Phase 3 Data Showing Gilotrif® (Afatinib) Extends Overall Survival In Lung Cancer Patients Whose Tumors Have The Most Common EGFR Mutation Compared With Chemotherapy 1/12/2015
GW Pharmaceuticals (GWPH) Falls as Cannabis Drug Fails Key Cancer Pain Study 1/9/2015
Regeneron (REGN) And Sanofi (SAN.PA) Announce Positive Topline Results From First Phase 3 Trials Evaluating Monthly Dosing Of Alirocumab In Patients With Hypercholesterolemia 1/9/2015
Portola Pharmaceuticals, Inc. Announces Phase 3 ANNEXA-R Study Of Andexanet Alfa And Factor Xa Inhibitor XARELTO® (Rivaroxaban) Met Primary Endpoint With High Statistical Significance 1/9/2015
Ligand Pharmaceuticals Inc. (LGND) Partner Retrophin (RTRX) Receives Orphan Drug Designation For Sparsentan 1/9/2015
Shield Therapeutics Announces The Publication Of The AEGIS Feraccru Phase 3 Pivotal Trial Manuscript In The Inflammatory Bowel Disease Journal 1/9/2015
AbbVie (ABBV), Neurocrine Biosciences, Inc. (NBIX) Drug Successful in Late Stage Endometriosis Trial 1/8/2015
Synergy Pharmaceuticals Completes Patient Enrollment For The First Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation 1/8/2015
Novartis AG (NVS) Announces Robust Phase 3 Results For QVA149 And NVA237 And Submits Regulatory Applications To U.S. FDA 1/8/2015
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.)'s Lead Candidate Delafloxacin Yields Positive Top-Line Results In Phase 3 Study In Patients With ABSSSI 1/8/2015
Dermira And UCB SA Announce Start Of Phase 3 Program For CIMZIA® (Certolizumab Pegol) In Psoriasis 1/8/2015
Versartis, Inc. (VSAR) Initiates Global Phase 3 Study Of VRS-317 In Children With Growth Hormone Deficiency 1/8/2015
Chimerix, Inc. (CMRX) Provides Update On Brincidofovir Pivotal Phase 3 Advise Trial For The Treatment Of Adenovirus 1/8/2015
Amicus Therapeutics, Inc. (FOLD) Announces Positive Phase 3 Data On Cardiac Endpoints From Fabry Monotherapy Study 011 And Long Term Extension Study 1/8/2015
Merrimack Pharmaceuticals Inc. (MACK) Announces Oral Presentation Of Additional Analyses Of MM-398 Phase 3 NAPOLI-1 Study At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 1/8/2015
GW Pharmaceuticals (GWPH) And Otsuka Pharmaceutical Co., Ltd. Announce Results In First Of Three Sativex® Phase 3 Cancer Pain Trials 1/8/2015
FDA Grants Soligenix (SNGX) "Fast Track" Designation For SGX301 For The First-Line Treatment Of Cutaneous T-Cell Lymphoma 1/7/2015
ContraVir Pharmaceuticals Granted FDA Meeting To Discuss Proposal For Phase 3 Trial Of FV-100 1/7/2015
Mirati Therapeutics  (MRTX) Doses First Patient In Investigator-Sponsored Phase 2 Study Of Mocetinostat In Non-Hodgkin's Lymphoma 1/6/2015
TONIX Pharmaceuticals, Inc. (TNXP) Provides Clinical And Regulatory Update On Its Continued Development Of TNX-102 SL In Fibromyalgia 1/6/2015
Alkermes plc (ALKS) Announces Positive Results From Study Of ALKS 5461 For Treatment Of Major Depressive Disorder 1/6/2015
Versartis, Inc. (VSAR) Announces Positive 12 Month Data For VRS-317 from Ongoing Extension Study 1/5/2015
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy In Previously Untreated And Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients 1/5/2015
Cerus Corporation (CERS) Reports EU Phase 3 Clinical Trial Of INTERCEPT Red Blood Cells Met Primary Endpoint 1/5/2015
CEL-SCI (CVM)’s 2014 Patient Enrollment Increases Eight-Fold Over 2013 In Its Phase 3 Head And Neck Cancer Trial 1/5/2015
Cempra Pharmaceuticals, Inc. (CEMP) Surges as Lead Oral Antibiotic Meets Main Goal in Phase 3 Study 1/5/2015
Can-Fite BioPharma (CFBI) Completes The Design Of The Rheumatoid Arthritis Phase 3 Study Of Its Lead Drug Candidate Cf101 12/30/2014
Intersect ENT Announces Enrollment Of First Patient In Phase 3 Study Of In-Office Treatment For Recurrent Chronic Sinusitis 12/30/2014
Palatin Technologies (PTN) Announces Start Of Bremelanotide Phase 3 Program For Female Sexual Dysfunction 12/29/2014
RegeneRx Biopharmaceuticals, Inc. (RGRX) Partner Submits Phase 2B/3 IND To Korean Health Authority For RGN-259 For The Treatment Of Dry Eye Syndrome 12/29/2014
Five Quick Takes on Stem Cells: CIRM, Sanford-Burnham Medical, BioWorld, StemCells (STEM), Cellular Dynamics 12/24/2014
Roche (RHHBY) Suffers A Double Blow As Breast Cancer, Alzheimer’s Drug Studies Fail; Pulls Plug On ALZ's Drug Development 12/23/2014
Provectus Biopharmaceuticals Inc. To Meet With FDA On Operational Aspects Of PV-10 Phase 3 Melanoma Study With Aim To Maximize Speed Of Enrollment 12/22/2014
Creative Bioarray Introduces Mini-Centrifuges With Outstanding Performance 12/22/2014
Radius (RDUS) Announces Positive Phase 3 Top-Line Results For Its Investigational Drug Abaloparatide-SC In Postmenopausal Women With Severe Osteoporosis 12/22/2014
TiGenix Submits Its Pivotal US Trial Design For Cx601 To The FDA For Special Protocol Assessment 12/22/2014
Receptos (RCPT) Initiates SUNBEAM Phase 3 Trial Of RPC1063 In Relapsing Multiple Sclerosis 12/22/2014
TetraPhase Pharmaceuticals (TTPH) Surges As Antibiotic Succeeds In Late-Stage Trial 12/19/2014
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine Hits Goal In Late-Stage Study 12/19/2014
Pfizer (PFE) Shows Off Significant Data From Pregabalin CR Phase 3 12/19/2014
ImmunoGen, Inc. (IMGN) Reports Roche (RHHBY) Has Provided An Update On The MARIANNE Trial 12/19/2014
Roche (RHHBY) Provides Update On Gantenerumab Development Programme 12/19/2014
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation In The United States And The European Union For The Treatment Of Malignant Pleural Mesothelioma 12/19/2014
Cardio3 BioSciences Announces The Enrolment Of The 240th Patient For Its CHART-1 Phase 3 Clinical Trial For The Treatment Of Heart Failure 12/19/2014
SoCal's Auspex Pharmaceuticals (ASPX) Soars 90% On Huntington's Disease Drug Trial Data 12/18/2014
Pivotal Phase 3 Study Of GlaxoSmithKline (GSK) Shingles Candidate Vaccine Meets Its Primary Endpoint 12/18/2014
Pfizer (PFE) Reports Top-Line Results From A Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation As A Treatment For Patients With Postherpetic Neuralgia 12/18/2014
TetraPhase Pharmaceuticals (TTPH) Announces Positive Top-Line Results From Phase 3 IGNITE 1 Clinical Trial Of Eravacycline In Complicated Intra-Abdominal Infections 12/18/2014
Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation 12/18/2014
LFB S.A. Announces Achievement Of Patient Enrollment Target For Persept 1 Program For The Evaluation Of Recombinant Factor Seven Efficacy By Prospective Clinical Trials 12/18/2014
Extab Corporation Announces Positive Data From Phase 3 Clinical Study Of Cytisine As A Smoking Cessation Aid Published In The New England Journal Of Medicine 12/18/2014
Hutchison Medipharma Starts Phase III Trial Of Cancer Drug 12/18/2014
RedHill Biopharma Ltd. (RDHL) Announces First Patients Enrolled In The Phase 3 Study Of RHB-102 (BEKINDA(TM)) For Gastroenteritis And Gastritis 12/17/2014
Sophiris Bio Inc. (SPHS) Tanks As Phase 3 Data Indicates Drug May Not Be Effective 12/16/2014
Celldex Therapeutics, Inc. (CLDX) Announces Completion Of Enrollment In Phase 3 Study Of Rindopepimut In Frontline Glioblastoma 12/16/2014
Cyclacel Pharmaceuticals, Inc. (CYCC) Announces Enrollment Of 486 Patients, DSMB Recommendations And That The Seamless Phase 3 Trial Of Sapacitabine In AML Will Continue To Final Analysis 12/16/2014
Ultragenyx Pharmaceuticals (RARE) Announces Initiation Of Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7 12/15/2014
Sophiris Bio Inc. (SPHS) Reports Administrative Interim Analysis For The "PLUS-1" Phase 3 Trial Of PRX302 For Benign Prostatic Hyperplasia 12/15/2014
Acorda Therapeutics (ACOR) Announces Initiation Of Phase 3 Clinical Trial For Dalfampridine In Post-Stroke Walking Deficits 12/15/2014
Novartis AG (NVS) Psoriasis Drug Tops Johnson & Johnson (JNJ)'s Stelara In Late-Stage Study 12/12/2014
Nektar Therapeutics (CA) (NKTR) Presents Data On Target-Specific Biomarkers From Circulating Tumor Cell Sub-Study Of Phase 3 BEACON Study Of Etirinotecan Pegol (NKTR-102) In Patients With Advanced Breast Cancer 12/12/2014
BeyondSpring To Start China-U.S. Phase 3 Trial Of Novel Cancer Drug 12/12/2014
Ipsen (IPN.PA) Announces That The International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating The Use Of Ovarian Suppression To Adjuvant Treatment With Tamoxifen 12/12/2014
Alnylam Pharmaceuticals (ALNY) Initiates ENDEAVOUR Phase 3 Clinical Trial With Revusiran (ALN-Ttrsc), An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR Cardiac Amyloidosis 12/12/2014
Janssen Research & Development Release: Data From The EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented At San Antonio Breast Cancer Symposium 12/12/2014
Head-To-Head Psoriasis Study Demonstrates Superiority Of Novartis AG (NVS) Cosentyx™ To Stelara® In Clearing Skin 12/12/2014
Vectura Group plc (VEC.L)’s Investigational Drug/Device Combination VR475 Met Primary Endpoint And Has Shown Significant Clinical Benefit In A Phase 2b/3 Trial In Severe Asthma Patients 12/11/2014
Anergis Starts Phase II Dose Ranging Trial With Birch Pollen Allergy Vaccine AllerT 12/11/2014
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO)’s Brexpiprazole Demonstrates Statistically Significant Effects In New Phase 3 Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting 12/11/2014
Phase 3 Results From German Breast Group (GBG) Demonstrates Superior Activity In High Risk Early Breast Cancer For Nab-Paclitaxel (Abraxane®) Vs. Solvent-Based Paclitaxel 12/11/2014
Macrocure (MCUR) Announces Completion Of Mechanism Of Action Study 12/11/2014
Galena Biopharma  (GALE) Presents HER2 Screening Data Including Preliminary Leica Bond Oracle™ Results From the Phase 3 NeuVax™ (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS) 12/11/2014
EXCLUSIVE: AbbVie (ABBV) VP Says New Cancer Drug Could Treat Other Diseases 12/11/2014
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY) ADCETRIS Phase 3 Demonstrated Statistically Significant Improvement In Progression-Free Survival 12/10/2014
Bavarian Nordic (BAVA.CO) Reaches Enrollment Target In The Pivotal Phase 3 Study Of PROSTVAC® In Prostate Cancer 12/10/2014
Acorda Therapeutics (ACOR) Announces Initiation Of Phase 3 Trial Of CVT-301 In Parkinson’s Disease 12/10/2014
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO) Present Phase 3 Data On Brexpiprazole As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting 12/10/2014
Eli Lilly (LLY), Incyte Corporation (INCY) Arthritis Drug Meets Endpoint In Phase 3 12/10/2014
Bristol-Myers Squibb Company (BMY) Release: Anticoagulant Effect Of Eliquis (Apixaban) Reversed By Two Separate 4-Factor Prothrombin Complex Concentrates In Healthy Subjects 12/9/2014
New Data At American Society of Hematology 2014 Highlight Progress Of Pfizer (PFE)’s Growing Portfolio In Blood Cancers 12/9/2014
Celgene (CELG) Release: Data Presented On REVLIMID® (lenalidomide) Compared With Investigators’ Choice In Relapsed/Refractory Diffuse Large B-Cell Lymphoma 12/9/2014
Celgene (CELG) Release: Results From Phase 3 Study Of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence In Patients With Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented At American Society of Hematology 12/9/2014
Novartis AG (NVS) Release: Six-Year Pivotal Study Data Reinforce The Superiority Of Tasigna Over Gleevec In Newly-Diagnosed Patients With Ph+ CML 12/9/2014
New Trial Initiated Evaluating Amgen (AMGN)'s Talimogene Laherparepvec In Combination With Merck & Co. (MRK)'s Anti-PD-1 Therapy KEYTRUDA (Pembrolizumab) For Advanced Melanoma 12/9/2014
Pharmacyclics, Inc. (PCYC) Release: Longer Follow-Up IMBRUVICA (ibrutinib) Treatment Demonstrates Sustained Efficacy In Patients With Difficult-To-Treat Chronic Lymphocytic Leukemia (CLL) 12/9/2014
Janssen Research & Development Release: IMBRUVICA (ibrutinib) Shows Sustained Progression-Free Survival In Patients With High-Risk Chronic Lymphocytic Leukemia With Genetic Mutation 12/9/2014
CTI BioPharma Announces Presentation Of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance In FLT3-ITD Positive AML Cells 12/9/2014
ContraVir Pharmaceuticals Initiates Pharmacokinetic Study Of Lead Antiviral FV-100 For Treating Shingles 12/9/2014
Pharmacyclics, Inc. (PCYC) Release: Longer Follow-Up IMBRUVICA (ibrutinib) Treatment Demonstrates Sustained Efficacy In Patients With Difficult-To-Treat Chronic Lymphocytic Leukemia (CLL) 12/9/2014
Celgene (CELG) Release: Results From Phase 3b Study Of POMALYST®/IMNOVID® (Pomalidomide) Plus Low-Dose Dexamethasone In Patients With Relapsed And Refractory Multiple Myeloma Presented At American Society of Hematology 12/9/2014
Celgene (CELG) Release: Additional Analyses Of High-Risk Patients From Phase 3 Study (AML-001) OF Vidaza® (Azacitidine For Injection) In Acute Myeloid Leukemia Presented At American Society of Hematology 12/9/2014
SSF's Sunesis Pharmaceuticals, Inc. (SNSS) Believes It Can End 40 Year AML Drought Despite "Failed" Phase 3 Study 12/8/2014
Phase 3 Data Shows Sandoz, Inc.'s Investigational Biosimilar Filgrastim Has Similar Safety And Efficacy As Amgen (AMGN)'s NEUPOGEN® 12/8/2014
Amgen (AMGN) And Onyx Pharmaceuticals, Inc. (ONXX) Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 12/8/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Presentation Of Results From Phase 3 VALOR Trial At American Society of Hematology Annual Meeting 12/8/2014
CTI BioPharma Announces Comprehensive Kinome Analysis That Demonstrates Pacritinib Inhibits Kinases Linked To A Spectrum Of Blood-Related Cancers 12/8/2014
Novo Nordisk A/S (NVO) Release: Novoeight Phase 3 Data Show Reduction In Annualised Bleeding Rate Over Time In People With Haemophilia A 12/8/2014
American Society of Hematology Release: Novel Combinations Of New And Existing Therapies Yield Promising Results for Leukemia Patients With Poor Prognoses 12/8/2014
Vital Therapies, Inc. (VTI) (VTL) Announces First Subject Enrolled In VTI-210 And Provides Update On Enrollment In VTI-208 12/8/2014
BioDelivery Sciences International (BDSI) Announces Completion Of Randomization In Phase 3 Trial Of Clonidine Topical Gel For The Treatment Of Painful Diabetic Neuropathy 12/8/2014
Upsher-Smith Laboratories Presents New Data From Year-Long, Open-Label Extension Study Of Qudexy XR (Topiramate) Extended-Release Capsules At 68th Annual American Epilepsy Society Meeting 12/8/2014
Orexo Features Positive Results From The ISTART Study At The 2014 AAAP Meeting 12/8/2014
ACADIA Pharmaceuticals, Inc. (ACAD) Presents Caregiver Burden Data At The International Congress Of Non-Motor Dysfunctions In Parkinson’s Disease And Related Disorders 12/8/2014
CEL-SCI (CVM) Expands Its Pivotal Phase 3 Immunotherapy Head And Neck Cancer Trial With Addition Of 7 More Clinical Sites 12/8/2014
Seattle Genetics, Inc. (SGEN) And Takeda (TKPYY) Report Phase 3 AETHERA Clinical Trial Data From ADCETRIS® (Brentuximab Vedotin) In Post-Transplant Hodgkin Lymphoma Patients At Risk Of Relapse At American Society of Hematology Annual Meeting 12/8/2014
ERYtech Pharma Reports Additional Positive Phase 3 Results From Clinical Study With ERY-ASP/GRASPA® In Acute Lymphoblastic Leukemia 12/8/2014
Celgene (CELG) Release: Age, Renal Impairment and Depth of Response Analyses of the First™ (MM-020/IFM 07-01) Study of Continuous REVLIMID® (Lenalidomide) Plus Low-Dose Dexamethasone In Newly-Diagnosed Multiple Myeloma Presented at American Society of Hematology 12/8/2014
Shire Release: Phase 3 Guanfacine Hydrochloride Extended Release (GXR) Study Shows Improvement In Core Symptoms Of Attention-Deficit/Hyperactivity Disorder (ADHD) In Children And Adolescents 12/8/2014
PaxVax, Inc. Announces Primary Endpoints Met In Phase 3 Cholera Vaccine Trial 12/8/2014
Novartis AG (NVS) Copy Of Amgen (AMGN) Cancer Drug Shows Similar Efficacy 12/8/2014
Amgen (AMGN)'s Kyprolis Delivers In Phase 3 Multiple Myeloma Study 12/8/2014
FDA Grants Breakthrough Therapy Status To Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Ixazomib 12/8/2014
Intercept Pharmaceuticals (ICPT) Announces Publication Of Meta-Analysis From The Global PBC Study Group In Gastroenterology 12/5/2014
CytRx Corporation (CYTR) Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials 12/4/2014
Phase 3 Results Published In The New England Journal of Medicine Show Superiority Of Pfizer (PFE)’s XALKORI® (crizotinib) Compared To Platinum-Based Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer 12/4/2014
Investors Cheer As Biogen Idec (BIIB)'s BIIB037 Skips To Phase 3 For Alzheimer's 12/4/2014
ADMA Biologics, Inc.'s Primary Endpoint Achieved, Touts Positive Phase 3 Data 12/3/2014
Novartis AG (NVS) Flu Vaccine FLUAD Suspended Following 13 Reported Deaths 12/3/2014
Novartis AG (NVS) Fingolimod Ph3 Trial In PPMS Fails To Meet Primary Goal 12/3/2014
Prothena Corporation plc Targets Rare Protein-Misfolding Disease In Late-Stage Study 12/3/2014
First MS Patients In The U.S. Receive Genzyme Corporation (GENZ)’s Lemtrada Following FDA Approval 12/3/2014
Jazz Pharmaceuticals (JAZZ) Announces First Patients Enrolled In Phase 3 Trial Of Xyrem (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy 12/3/2014
Prothena Corporation plc Initiates NEOD001 Global Phase 3 Registrational Trial Based On Positive Results In Ongoing Phase 1/2 Study Of NEOD001 In Patients With AL Amyloidosis 12/3/2014
BeyondSpring Pharmaceuticals To Conduct Phase 3 Trial Of Lead Candidate Plinabulin In NSCLC 12/3/2014
Exelixis, Inc. (EXEL) COMET-2 Ph3 Cabozantinib Trial Fails To Meet Primary Endpoint 12/2/2014
Aerie Pharmaceuticals, Inc. (AERI) Completes Enrollment In Phase 3 Registration Trial ("Rocket 1") Of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma 12/2/2014
CEL-SCI (CVM) Quarterly Patient Enrollment In Its Head And Neck Cancer Phase 3 Trial Increases Eight Fold Over Same Prior Year Period 12/2/2014
Exelixis, Inc. (EXEL) Announces Results From The COMET-2 Pivotal Phase 3 Trial Of Cabozantinib In Men With Metastatic Castration-Resistant Prostate Cancer 12/1/2014
Mylan Inc. (MYL), Gilead Sciences, Inc. (GILD) Ink Agreement Covering Non-Exclusive TAF Rights 12/1/2014
Celator Pharmaceuticals, Inc. Announces Data And Safety Monitoring Board Recommendation To Continue Phase 3 Study Of CPX-351 12/1/2014
ImmunoCellular Therapeutics, Ltd (IMUC) Receives Positive Regulatory Feedback From European Medicines Agency On Advancing ICT-107 To Phase 3 Program 12/1/2014
AEterna Zentaris (AEZS) And Sinopharm A-Think Sign Master Collaboration Agreement For Zoptarelin Doxorubicin In China 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
Zogenix, Inc. (ZGNX) Release: Results Of Long-Term, Open-Label Study Published In The Journal Of Pain Research Demonstrate The Safety, Tolerability And Effectiveness Of Zohydro ER 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
Amgen (AMGN), AstraZeneca PLC (AZN)'s Brodalumab Phase 3 Study Met All Primary Endpoints Against Johnson & Johnson (JNJ)'s Stelara 11/26/2014
Amgen (AMGN) Terminates All Rilotumumab Clinical Trials For Advanced Gastric Cancer 11/26/2014
FDA Requires Additional Data On Bristol-Myers Squibb Company (BMY)' Hep C Daclatasvir 11/26/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 3 Study Of ISIS-SMN Rx In Children With Spinal Muscular Atrophy 11/25/2014
R-Tech Ueno Received Orphan Drug Designation For Unoprostone Isopropyl (Development Code:UF-021) For The Treatment Of Retinitis Pigmentosa From MHLW 11/25/2014
Intra-Cellular Therapies, Inc. Announces Enrollment Of First Patient In Phase 3 Trial Of ITI-007 For The Treatment Of Schizophrenia 11/25/2014
Ferring Pharmaceuticals Release: New Data From A Pooled Analysis Shows Improved Overall Survival For Prostate Cancer Patients Treated With FIRMAGON® (Degarelix) Compared To LHRH Agonists 11/25/2014
Onxeo Announces Positive DSMB Recommendation For Its Phase 3 Trial With Livatag® In Primary Liver Cancer 11/24/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Publication Of REVEAL-1 Trial Results In The British Journal Of Haematology 11/24/2014
Regeneron (REGN), ReGen Therapeutics Plc (RGT.L) Eczema Drug Dupilumab Gets FDA Breakthrough Therapy Designation 11/24/2014
Top 10 Countries For Diabetes Clinical Research 11/21/2014
Relypsa, Inc. (RLYP) Announces Data Published In The New England Journal of Medicine For Pivotal Phase 3 Program Of Patiromer FOS For The Treatment Of Hyperkalemia 11/21/2014
ZS Pharma (ZSPH) Announces Publication Of Results From Phase 3 Study Of ZS-9 In Patients With Hyperkalemia In The New England Journal of Medicine 11/21/2014
Immunomedics, Inc. (IMMU) Announces Orphan Drug Designation For Veltuzumab For The Treatment Of Pemphigus 11/21/2014
Immunomedics, Inc. (IMMU) Presents Clinical Data On Novel Antibody-Drug Conjugates For Solid Cancer Therapy 11/21/2014
Sanofi (SAN.PA) And Regeneron (REGN)'s Alirocumab Ph3 Trials Met Primary Efficacy Endpoint 11/20/2014
Charleston Laboratories, Inc. And Daiichi Sankyo, Inc. (4568.t) Initiate Two Phase 3 Clinical Trials On Charleston's Lead Product, CL-108 11/20/2014
TrovaGene, Inc. Releases Clinical Study Results For The Detection And Monitoring Of KRAS Mutations In Circulating Tumor DNA Of Colorectal Cancer Patients 11/20/2014
Auxilium Pharmaceuticals (AUXL) Presents XIAFLEX For Peyronie's Disease Data At SMSNA Scientific Meeting 11/20/2014
Titan Pharmaceuticals (TTP) Announces Completion Of Enrollment In Phase 3 Study Of Probuphine For Opioid Dependence 11/20/2014
Merrimack Pharmaceuticals Inc. (MACK) Receives FDA Fast Track Designation For MM-398 In Post-Gemcitabine Metastatic Pancreatic Cancer 11/19/2014
FDA Puts Partial Hold On CytRx Corporation (CYTR)'s Aldoxorubicin Clinical Trials 11/19/2014
SOTIO Initiates US Part Of VIABLE, A Global Phase III Clinical Trial For Prostate Cancer Immunotherapy Treatment With DCVAC/PCa 11/19/2014
Amgen (AMGN) Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 11/19/2014
Genzyme Corporation (GENZ) And Isis Pharmaceuticals, Inc. (ISIS) Present KYNAMRO® Clinical Data At American Heart Association 11/19/2014
ZS Pharma (ZSPH) Presents Positive Results From HARMONIZE (ZS004), A Second Phase 3 Clinical Trial Of ZS-9 In Patients With Hyperkalemia, At The American Heart Association Scientific Meeting And Announces Simultaneous Publication Of Results In JAMA 11/17/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Publication Of Phase 3 Study Of Once Daily Envarsus® XR Demonstrating Non-Inferiority Vs. Twice-Daily Tacrolimus In De Novo Kidney Transplant Patients 11/17/2014
Novartis Pharmaceutical Corporation (NVS) AIN457 (secukinumab) Showed Significant Symptom Improvement In Two Pivotal Phase 3 ankylosing spondylitis Studies 11/17/2014
TissueGene, Inc. Receives Recommendations From FDA On Pathway To Phase 3 Trial Of TG-C For Treatment Of Osteoarthritis Of The Knee 11/17/2014
Keryx Biopharmaceuticals (KERX) Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study 11/17/2014
Amicus Therapeutics, Inc. (FOLD) Announces Positive Phase 3 Data On Cardiac And Composite Endpoints From Fabry Monotherapy Study 012 At American Society of Nephrology 11/17/2014
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company (BMY) And Pfizer (PFE) Announce Statistically Significant Results From The First Part Of The Phase 3 ANNEXA(TM)-A Studies Of Investigational Andexanet Alfa With Eliquis (Apixaban) 11/17/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Late-Breaking Presentation Of Phase 3 VALOR Trial At American Society of Hematology Annual Meeting 11/17/2014
Bristol-Myers Squibb Company (BMY) Release: Study Comparing Opdivo (Nivolumab) To Chemotherapy In Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor To Demonstrate A Survival Benefit In A Phase 3 Trial 11/17/2014